PEABODY, Mass., Oct. 14, 2025 — Privo Technologies, Inc., a clinical-stage biopharmaceutical company pioneering localized cancer therapies, announced the completion of enrollment in Arm 1 of the Phase 2 run-in portion of its ongoing Phase 2/3 clinical trial (CLN-004) evaluating PRV111, a nano-engineered chemotherapy patch for oral cavity cancers. The data from this Phase 2 stage are being analyzed for submission to the U.S. Food and Drug Administration (FDA) before progressing to Phase 3 enrollment. This milestone underscores Privo’s commitment to developing therapies that spare patients from invasive surgery while preserving quality of life.
Science Significance
PRV111 leverages Privo’s proprietary Programmed Release Vehicle (PRV) platform, a family of nano-engineered drug-delivery systems designed to deliver high concentrations of chemotherapy directly to tumors while minimizing systemic exposure. The PRV111 patch adheres directly to oral lesions, delivering cisplatin nanoparticles trans-mucosally to maximize local penetration and tumor coverage. The non-invasive, localized approach aims to preserve surrounding healthy tissue, reduce systemic toxicity, and maintain essential functions such as speech, swallowing, and appearance. Early clinical experience, including the first-in-human CLN-001 trial, demonstrated promising local tumor responses with no systemic toxicity, published in Nature Communications and highlighted by Forbes for its innovative localized drug delivery.
Regulatory Significance
The CLN-004 study is an adaptive, open-label Phase 2/3 clinical trial evaluating the safety, tolerability, and preliminary efficacy of PRV111 in oral carcinoma in situ (CIS) and high-grade oral dysplasia (HGD). Completion of Phase 2 enrollment is a key regulatory milestone, enabling Privo to submit the dataset to the FDA to support the design and execution of the pivotal Phase 3 portion of the trial. Early observations indicate that patients with favorable local tumor responses could avoid planned surgical procedures, highlighting the potential for PRV111 to provide tissue-sparing, non-surgical treatment options pending further regulatory review.
Business Significance
Advertisement
Privo Technologies’ progress with PRV111 positions the company at the forefront of localized oncology drug development, offering a novel approach in a market dominated by systemic chemotherapy and invasive surgery. By demonstrating clinical efficacy and safety with a tissue-preserving therapy, Privo aims to differentiate its platform in oncology, potentially capturing early adoption in oral cavity cancer management. The CLN-004 trial’s multi-site enrollment across the U.S. also supports scalable commercial potential, reinforcing Privo’s mission to develop patient-centric cancer therapies with global applicability.
Patients’ Significance
Oral cavity cancers often require extensive surgical excision, impacting patients’ speech, swallowing, and appearance. PRV111’s localized patch approach offers a potential alternative, eliminating visible or measurable tumors while preserving healthy tissue. Initial Phase 2 run-in observations are highly encouraging, with no systemic toxicity and evidence that some patients could forgo planned surgeries. This approach promises enhanced quality of life, reduced recovery time, and potentially lower recurrence risk, addressing a critical unmet need in early-stage oral cancer management.
Policy Significance
PRV111’s development highlights the growing role of localized drug delivery in cancer care, potentially influencing future clinical guidelines for non-invasive therapy in early-stage oral lesions. Positive outcomes could support regulatory and payer adoption of tissue-sparing treatments, advancing policy frameworks that prioritize patient-centric oncology approaches while reducing healthcare burden from invasive surgery.
Transaction Highlights
The completion of Phase 2 enrollment in the CLN-004 study marks a critical milestone for Privo Technologies, demonstrating the safety and localized efficacy of PRV111 in treating oral cavity lesions. Initial observations from Arm 1 indicate that some patients with favorable local responses could avoid planned surgical procedures, highlighting the potential of a tissue-sparing, non-invasive approach. These results build upon Privo’s earlier Phase 1 experience (CLN-001), which also showed promising local tumor responses without systemic toxicity. With Phase 2 data now being analyzed for FDA submission, the findings will guide the design of the pivotal Phase 3 trial, further advancing Privo’s mission to develop patient-focused, minimally invasive cancer therapies that maximize efficacy while preserving quality of life.
Source: Privo Technologies Press Release
